
March 11 (Reuters) - Regenxbio Inc RGNX.O:
REGENXBIO REPORTS NEW POSITIVE INTERIM DATA FROM PHASE I/II AFFINITY DUCHENNE® TRIAL OF RGX-202
REGENXBIO INC - NO SERIOUS ADVERSE EVENTS OBSERVED IN PHASE I/II STUDY
REGENXBIO INC - PIVOTAL TOPLINE DATA EXPECTED IN Q2 2026
REGENXBIO INC - TO REQUEST PRE-BLA MEETING WITH FDA IN MID-2026